Drugs / 4SC-205
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01065025 | Jan 2010 → Apr 2015 | lymphoma | 4SC AG | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2015-06-03 | 4SC AG | Results Press Release: 4SC presents final results from Phase I AEGIS trial as well as rationale for daily dosing scheme of 4SC-205 cancer compound at ASCO 4sc.com ↗
A recommended Phase II dosage was established. |
All press releases naming this drug 2 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4SC-205 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01065025 ↗ |
| Action | Inhibit | “oral inhibitor of Kinesin-spindle Protein, Eg5” NCT01065025 ↗ |
| Route | Oral | “Repeated ascending oral doses” NCT01065025 ↗ |